Document is current

Article History

Received: 9 November 2020

Accepted: 28 April 2021

First Online: 14 June 2021

Competing interests

: All authors affiliated with AXON Neuroscience SE, AXON Neuroscience R&D Services SE or AXON Neuroscience CRM Services SE (P.N., B.K., S.K., E.K., L. Fialova, N.P.-I, M. Smisek, J. Hanes, E. S., A. K., V. P., P. K., M. P., J. G., M. C., P. F., J. P., M. Samcova, C. P.-G., R. Sivak, M. F., M. Ondrus, M. N. and N. Z.) receive salary from the respective companies. T.H. receives salary from AXON Neuroscience R&D services SE. R. Schmidt and S.R. have received personal fees and honoraria for image analyses from AXON Neuroscience. The investigators’ institutions have received payments on a per-patient per-visit basis. P. S. has received consultancy/speaker fees (paid to the institution) from AXON, Biogen, People Bio, Roche (Diagnostics) and Novartis Cardiology. He is Principal Investigator of studies with Vivoryon, IONIS, CogRx, AC Immune and Toyama. He serves on the DSMB of Genentech anti-tau study. M. Otto reports personal fees from AXON Neuroscience. The investigator’s institution has received payments on a per-patient per-visit basis. B.W. reports personal fees from AXON Neuroscience. The investigator’s institution has received payments on a per-patient per-visit basis. J. Hort reports personal fees from AXON Neuroscience. The investigator’s institution has received payments on a per-patient per-visit basis. L. Froelich reports personal fees from AXON Neuroscience. The investigator’s institution has received payments on a per-patient per-visit basis. M.K.’s institution has received payments on a per-patient per-visit basis. M.R.’s institution has received payments on a per-patient per-visit basis. S.S.’s institution has received payments on a per-patient per-visit basis. J. Harrison reports receipt of personal fees in the past 2 years from AlzeCure, Aptinyx, Astra Zeneca, Athira Therapeutics, AXON Neuroscience, Axovant, Biogen Idec, BlackThornRx, Boehringer Ingelheim, Cerecin, Cognition Therapeutics, Compass Pathways, CRF Health, Curasen, EIP Pharma, Eisai, Eli Lilly, FSV7, G4X Discovery, GfHEU, Heptares, Ki Elements, Lundbeck, Lysosome Therapeutics, MyCognition, Neurocentria, Neurocog, Neurodyn Inc., Neurotrack, Novartis, Nutricia, Probiodrug, Regeneron, Rodin Therapeutics, Samumed, Sanofi, Servier, Signant, Syndesi Therapeutics, Takeda, Vivoryon Therapeutics, vTv Therapeutics and Winterlight Labs. Additionally, he holds stock options in Neurotrack Inc. and is a joint holder of patents with MyCognition Ltd. D.T.’s institution received payments from AXON Neuroscience for image processing during the conduct of the study.